Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9156 posts found.

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024 Research and Development Ear Nose & throat, Eli Lilly, clinical trial, sleep apnoea, tirzepatide

Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated that tizepatide injection (10mg or …
News

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024 Research and Development AbbVie, Immunology, Medincell, collaboration

Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and commercialise up to six next-generation …
News

Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy

April 17, 2024 Research and Development Intra-Cellular Therapies, Neurology, clinical trial, major depressive disorder, mental health

Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as an adjunctive therapy to antidepressants …
News

Novartis shares new data about Fabhalta for IgAN treatment

April 16, 2024 Research and Development Fabhalta, IgAN, Nephrology, Novartis, nephropathy

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN trial of Fabhalta (iptacopan), an …
News

Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment

April 15, 2024 Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma

Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …
News

Lipocine announces results from phase 2 trial for obesity drug

April 12, 2024 Research and Development Lipocine, Obesity, clinical trial, weight loss

Lipocine Inc has announced results from its phase 2 clinical trial (NCT04134091), which includes results for LPCN 2401, the company’s …
News

TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment

April 10, 2024 Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer

TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …
News

FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment

April 10, 2024 Research and Development FDA, Oncology, Oryzon, lung cancer

Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application …
News

Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine

April 8, 2024 Research and Development Cancer, Geneos Therapeutics, Oncology, clinical trial

Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from the full cohort of patients …
News

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

April 5, 2024 Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, lung cancer

AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically …
News

EnteroBiotix begins phase 2 trial of IBS treatment

April 3, 2024 Research and Development EnteroBiotix, Gastrointestinal tract, IBS, irritable bowel syndrome

EnteroBiotix has announced that it has dosed the first patient in its multi-centre, randomised, double-blind, placebo controlled clinical trial, which …
News

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

April 2, 2024 Research and Development AstraZeneca, Daiichi Sankyo, FDA, Oncology, bla, breast cancer

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan (Dato-Dxd) has been accepted in …
News

Heidelberg Pharma gains FDA ODD for ATAC candidate

March 27, 2024 Research and Development FDA, Oncology, heidelberg pharma, multiple myeloma

Heidelberg Pharma has announced that it has gained Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) …
News

Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment

March 26, 2024 Research and Development Cancer, Curve Therapeutics, HIF inhibition, Oncology, oncology

Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research in the Journal of the …
News

Sosei Heptares doses first patient in trial for inflammatory bowel disease treatment

March 21, 2024 Research and Development Gastrointestinal tract, Sosei Heptares, clinical trial, inflammatory bowel disease, phase 1 trial

Sosei Heptares has announced that it has dosed the first patient in its phase 1 trial assessing a novel EP4 …
News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024